Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
A Multicenter, non-interventional, prospective study to collect effectiveness and safety data in Chinese patients who have received Faslodex treatment under the condition of actual usage in clinical practice
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Chinese postmenopausal women with estrogen receptor positive, locally advanced or metastatic breast cancer Failure to previous anti-estrogen therapy, already received Faslodex 250mg treatment as determined by treating physician.
The prescription of the Faslodex is clearly separated from the decision to include the subject in the NIS, and is part of normal medical practice. The recruitment of the patient to the study should be within 1 month of the first Faslodex injection.
Provision of subject informed consent.
You may not be if
If participating in any controlled clinical trial, the subject cannot take part in this study.
Hypersensitivity to the active substance, or to any of the other excipients.
Pregnancy and lactation, or severe hepatic impairment.
